Department of Gynecologic Oncology, Ankara City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Baskent University, Ankara, Turkey.
Arch Gynecol Obstet. 2021 Nov;304(5):1279-1289. doi: 10.1007/s00404-021-06030-w. Epub 2021 Mar 27.
To clarify the prognostic value of the number of metastatic lymph nodes (mLNs) in squamous and non-squamous histologies among women with node-positive cervical cancer.
One hundred ninety-one node-positive cervical cancer patients who had undergone radical hysterectomy plus systematic pelvic and para-aortic lymphadenectomy followed by concurrent radiochemotherapy were retrospectively reviewed. The prognostic value of the number of mLNs was investigated in squamous cell carcinoma (SCC) v (n = 148) and non-SCC (n = 43) histologies separately with univariate log-rank test and multivariate Cox regression analyses.
In SCC cohort, mLNs > 2 was significantly associated with decreased 5-year disease-free survival (DFS) [hazard ratio (HR) = 2.06; 95% confidence interval (CI) 1.03-4.09; p = 0.03) and overall survival (OS) (HR = 2.35, 95% CI 1.11-4.99; p = 0.02). However mLNs > 2 had no significant impact on 5-year DFS and 5-year OS rates in non-SCC cohort (p = 0.94 and p = 0.94, respectively). We stratified the entire study population as SCC with mLNs ≤ 2, SCC with mLNs > 2, and non-SCC groups. Thereafter, we compared survival outcomes. The non-SCC group had worse 5-year OS (46.8% vs. 85.3%, respectively; p < 0.001) and 5-year DFS rates (31.6% vs. 82.2%, respectively; p < 0.001) when compared to those of the SCC group with mLNs ≤ 2. However, the non-SCC group and the SCC group with mLNs > 2 had similar 5-year OS (46.8% vs. 65.5%, respectively; p = 0.16) and 5-year DFS rates (31.6% vs. 57.5%, respectively; p = 0.06).
Node-positive cervical cancer patients who have non-SCC histology as well as those who have SCC histology with mLNs > 2 seem to have worse survival outcomes when compared to women who have SCC histology with mLNs ≤ 2.
明确在淋巴结阳性的宫颈癌患者中,鳞癌和非鳞癌组织中转移淋巴结(mLN)数量的预后价值。
回顾性分析了 191 例接受根治性子宫切除术加系统盆腔和主动脉旁淋巴结切除术,随后行同期放化疗的淋巴结阳性宫颈癌患者。分别对鳞癌(SCC)组(n=148)和非鳞癌(n=43)组进行单因素对数秩检验和多因素 Cox 回归分析,探讨 mLN 数量的预后价值。
在 SCC 组中,mLNs>2 与 5 年无病生存率(DFS)降低显著相关[风险比(HR)=2.06;95%置信区间(CI)1.03-4.09;p=0.03]和总生存率(OS)降低显著相关(HR=2.35,95%CI 1.11-4.99;p=0.02)。然而,mLNs>2 对非 SCC 组的 5 年 DFS 和 5 年 OS 率没有显著影响(p=0.94 和 p=0.94)。我们将整个研究人群分为 SCC 伴 mLNs≤2、SCC 伴 mLNs>2 和非 SCC 组。此后,我们比较了生存结果。与 SCC 伴 mLNs≤2 组相比,非 SCC 组的 5 年 OS 率(分别为 46.8%和 85.3%;p<0.001)和 5 年 DFS 率(分别为 31.6%和 82.2%;p<0.001)更差。然而,非 SCC 组和 mLNs>2 的 SCC 组的 5 年 OS 率(分别为 46.8%和 65.5%;p=0.16)和 5 年 DFS 率(分别为 31.6%和 57.5%;p=0.06)相似。
与 mLNs≤2 的 SCC 组织学患者相比,非 SCC 组织学患者以及具有 mLNs>2 的 SCC 组织学患者的生存结局似乎更差。